Eryped

Gastroparesis, Erythrasma, Whooping Cough + 60 more
Treatment
68 FDA approvals
20 Active Studies for Eryped

What is Eryped

ErythromycinThe Generic name of this drug
Treatment SummaryErythromycin is an antibiotic drug that stops the growth of certain bacteria. It was first discovered in 1952 and can be used to treat a variety of bacterial infections. Erythromycin is available in different forms, including IV, topical, and eye drops. It is part of the macrolide group of antibiotics, which includes azithromycin, clarithromycin, and spiramycin.
Erythrocin Stearateis the brand name
image of different drug pills on a surface
Eryped Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Erythrocin Stearate
Erythromycin
1964
261

Approved as Treatment by the FDA

Erythromycin, also known as Erythrocin Stearate, is approved by the FDA for 68 uses which include penicillins and Corynebacterium Infections .
penicillins
Corynebacterium Infections
Urethritis
Erythrasma
Postoperative Infections
Bordetella Pertussis Infection
uncomplicated endocervical infection
Staphylococcal Skin Infections
Pertussis
Bacterial Infections
Acne Vulgaris
Used to treat Acne Vulgaris in combination with Tretinoin
Acne Vulgaris
Used to treat predominant skin comedones, papules and pustules in combination with Tretinoin
pustular lesions
Used to treat pustular lesions in combination with Avobenzone
treponema pallidum infection
Communicable Diseases
Respiratory Tract Infections
Listeriosis
Corynebacterium minutissimum infection
Recurrent Upper and Lower Respiratory Tract Infections (RTIs)
Pneumonia, Mycoplasma
Whooping Cough
Staphylococcus (S.) Aureus Infection
Communicable Diseases
Conjunctivitis
Pneumonia
Listeria infection
Listeria monocytogenes infection
Acute Otitis Media caused by Haemophilus Influenzae
Used to treat Acute Otitis Media caused by Haemophilus Influenzae in combination with Sulfisoxazole
inflammatory papular lesions
Used to treat inflammatory papular lesions in combination with Avobenzone
Communicable Diseases
Bacterial Infections
Whooping Cough
Amebiasis
Common Cold
Rheumatic Fever
prophylaxis of Postoperative Infections
Communicable Diseases
prophylaxis of Rheumatic fever
Ureaplasma urethritis
penicillins
Upper Respiratory Tract Infection
Streptococcus Pneumoniae Infections
Streptococcus pyogenes
Staphylococcal Skin Infections
Urethritis
Urinary Tract Infection (UTI)
Legionella pneumophila
Primary Syphilis
Lower Respiratory Tract Infection (LRTI)
Intestinal amebiasis caused by entamoeba histolytica
Skin and skin structure infections
Diphtheria
urogenital infections during pregnancy
Corynebacterium Infections
diphtheria antitoxin
Bronchitis
Haemophilus Influenzae Infections
Used to treat Haemophilus Influenzae Infections in combination with null
Urethritis
Ureaplasma urealyticum
skin and subcutaneous tissue bacterial infections caused by streptococcus pyogenes
Whooping Cough
Chlamydia Trachomatis
patients with intolerance or contraindications to tetracycline use
Syphilis
First episode of rheumatic fever
Rheumatic Fever
Pneumococcal Infections
Sulfonamides

Effectiveness

How Eryped Affects PatientsErythromycin is an antibiotic that stops bacterial growth by preventing proteins from being made. It can be used to treat a variety of bacterial infections, but it is important to test for antibiotic resistance before administering the drug. Some strains of Haemophilus influenzae can be treated with a combination of erythromycin and sulfonamides, but Staphylococci may become resistant to erythromycin during treatment. Those taking erythromycin may experience pseudomembranous colitis, which can range from mild to life-threatening, and may also cause liver dysfunction, jaund
How Eryped works in the bodyErythromycin is an antibiotic that works by stopping bacteria from making proteins. It does this by targeting the ribosomal proteins in the cells of susceptible bacteria. This binding prevents the bacteria from forming proteins that it needs to replicate and grow, resulting in its death or control. Macrolides like erythromycin have a strong ability to bind to bacteria, which explains why they are so effective in treating a wide range of bacterial infections.

When to interrupt dosage

The dosage of Eryped is contingent upon the diagnosed condition, including Chlamydia Trachomatis, penicillins and Syphilis. The measure of dosage is dependent upon the administration procedure (e.g. Granule, for suspension or Tablet, film coated - Oral) detailed in the following table.
Condition
Dosage
Administration
Granuloma Inguinale
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Syphilis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Whooping Cough
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Acne Vulgaris
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Amebiasis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Endophthalmitis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Acute Otitis Media caused by Haemophilus Influenzae
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Ophthalmia neonatorum (gonococcal)
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Conjunctivitis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Communicable Diseases
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Respiratory Tract Infections
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Urethritis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Acne Vulgaris
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Urinary Tract Infection (UTI)
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Acne Vulgaris
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Chlamydia Trachomatis
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Staphylococcal Skin Infections
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Common Cold
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Streptococcus pyogenes
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral
Corynebacterium minutissimum infection
, 333.0 mg, 20.0 mg/mL, 0.02 mg/mg, 250.0 mg, 0.03 mg/mg, 0.005 mg/mg, 500.0 mg, 400.0 mg, 200.0 mg/mL, 400.0 mg/mL, 0.008 mL/mL, 0.0005 mg/mg, 20.0 mg, 600.0 mg, 1000.0 mg, 0.5 %, 4.0 %, 200.0 mg, 2.0 %, 50.0 mg/mL, 5.0 mg/mL, 15.0 mg/mL, 3.1 mg/mg, 100.0 mg/mL, 3.0 %, 125.0 mg/mL, 25.0 mg/mL, 250.0 mg/mL, 40.0 mg/mL, 0.0012 mg/mg, 0.12 mg/mg
, Kit, Tablet, delayed release - Oral, Oral, Topical, Solution - Topical, Gel, Solution, Gel - Topical, Tablet, film coated, Tablet, film coated - Oral, Capsule, delayed release - Oral, Capsule, delayed release, Ophthalmic, Ointment - Ophthalmic, Ointment, Tablet, Tablet - Oral, Tablet, delayed release, Suspension, Suspension - Oral, Granule, for suspension, Granule, for suspension - Oral, Capsule, delayed release pellets - Oral, Intravenous, Powder, for solution - Intravenous, Powder, for solution, Liquid - Oral, Liquid, Capsule, Capsule - Oral, Powder - Oral, Powder, Lotion, Lotion - Topical, Lotion; Swab, Lotion; Swab - Topical, Kit - Topical, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, lyophilized, for solution, Powder, for suspension, Powder, for suspension - Oral, Capsule, Delayed Release, Ointment - Topical, Capsule, coated pellets - Oral, Capsule, delayed release pellets, Capsule, coated pellets, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Wafer, Wafer - Oral, Swab, Swab - Topical, For suspension, For suspension - Oral, Tablet, coated - Oral, Tablet, coated, Powder, for solution - Oral, Capsule, Delayed Release - Oral

Warnings

Eryped has nine recognized contraindications, so it should not be ingested when afflicted with any of the conditions presented in the table below.Eryped Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Erythromycin may interact with Pulse Frequency
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Eryped.
Common Eryped Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Erythromycin.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Erythromycin.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Erythromycin.
Alpelisib
Major
The metabolism of Alpelisib can be decreased when combined with Erythromycin.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Erythromycin.
Eryped Toxicity & Overdose RiskThe toxic dose of erythromycin in rats is 9272 mg/kg. Signs of overdosing on erythromycin include diarrhea, nausea, stomach cramps, and vomiting. If an overdose occurs, the drug should be stopped right away and any unabsorbed drug should be quickly eliminated. Supporting treatments should be given. Erythromycin cannot be completely removed from the body through dialysis.
image of a doctor in a lab doing drug, clinical research

Eryped Novel Uses: Which Conditions Have a Clinical Trial Featuring Eryped?

53 active studies are currently being conducted to investigate the potential of Eryped in providing relief from Streptococcus pyogenes, Treponema pallidum infection and Rheumatic Fever.
Condition
Clinical Trials
Trial Phases
Acne Vulgaris
2 Actively Recruiting
Phase 1, Phase 2, Early Phase 1
Listeriosis
0 Actively Recruiting
Legionella pneumophila
0 Actively Recruiting
Urethritis
0 Actively Recruiting
Ureaplasma urealyticum
0 Actively Recruiting
Acute Otitis Media caused by Haemophilus Influenzae
0 Actively Recruiting
Gastroparesis
15 Actively Recruiting
Phase 3, Not Applicable, Phase 1, Early Phase 1
Acne Vulgaris
0 Actively Recruiting
Pneumococcal Infections
0 Actively Recruiting
Corynebacterium minutissimum infection
0 Actively Recruiting
Acne Vulgaris
0 Actively Recruiting
Urinary Tract Infection (UTI)
6 Actively Recruiting
Phase 1, Phase 3, Phase 4, Phase 2
Urethritis
0 Actively Recruiting
Listeria monocytogenes infection
0 Actively Recruiting
Chlamydia Trachomatis
0 Actively Recruiting
Conjunctivitis
0 Actively Recruiting
penicillins
2 Actively Recruiting
Early Phase 1, Phase 3
Primary Syphilis
0 Actively Recruiting
treponema pallidum infection
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting

Eryped Reviews: What are patients saying about Eryped?

1Patient Review
2/4/2011
Eryped for Bacterial Stomach or Intestine Infection caused by Anthrax
I felt nauseous and lost my appetite.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about eryped

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is erythromycin ethylsuccinate used to treat?

"Erythromycin is used to treat infections caused by bacteria. Additionally, it may be taken as a preventative measure to reduce the likelihood of developing certain bacterial infections. Erythromycin is in a class of antibiotics known as macrolides, which work by inhibiting the growth of bacteria."

Answered by AI

What bacteria is erythromycin used to treat?

"Erythromycin can be used to treat bacteria that causes infections of the skin and upper respiratory tract, including Streptococcus, Staphylococcus, Haemophilus, and Corynebacterium genera."

Answered by AI

How long is EryPed good for?

"After adding water to the powder, EryPed 200, EryPed 400, and EryPed Drops must be stored at 77°F (25°C) or below and used within 35 days; refrigeration is not required."

Answered by AI

What is EryPed used to treat?

"EryPed is a prescription medication used to treat Intestinal Amebiasis, Legionnaire Disease, Pertussis, Streptococcal Infections, Primary Syphilis, and Urethritis. EryPed may be used alone or combined with other medications. EryPed belongs to a class of drugs called Macrolides, which work by killing bacteria or preventing their growth."

Answered by AI

Clinical Trials for Eryped

Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA
The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.
Recruiting
Has No Placebo
Children's Healthcare of Atlanta (+3 Sites)Todd Florin, MD, MSCE
Have you considered Eryped clinical trials? We made a collection of clinical trials featuring Eryped, we think they might fit your search criteria.Go to Trials
Image of Children's Community Pediatrics Brentwood in Pittsburgh, United States.

AI Diagnostic Support for Ear Infections

6 - 24
All Sexes
Pittsburgh, PA
Ear infections are common in young children with cold symptoms, but they can be difficult to diagnose due to small ear canals, child movement, and limited viewing time. In this study, investigators will take photos of the eardrums of children 6-24 months of age with upper respiratory symptoms. The photos will be reviewed by imaging software enhanced with artificial intelligence (AI app) to determine whether the AI app changes how ear infections are diagnosed and treated. The AI app has undergone rigorous study and was found to be highly accurate; but how using this technology affects the diagnosis and treatment by clinicians has not been studied. This research may help improve diagnostic accuracy for ear infections and ensure antibiotics are prescribed only for those children who have definite ear infections.
Waitlist Available
Has No Placebo
Children's Community Pediatrics Brentwood (+1 Sites)Timothy R Shope, MD, MPHMerck Sharp & Dohme LLC
Image of Maternity Centre of Hamilton in Hamilton, Canada.

Rapid Test for Syphilis

13 - 49
All Sexes
Hamilton, Canada
The goal of this clinical trial is to learn if a finger-prick blood test for rapid diagnosis of syphilis infection can be implemented in a low-barrier prenatal clinic for people at risk of syphilis in pregnancy. The test gives results in 5 minutes and also tests for HIV. The main questions the study aims to answer are: * How often do pregnant people at risk of syphilis agree to the rapid test? * How well do healthcare providers perform the rapid test? * Does the rapid test speed up diagnosis and treatment of syphilis in pregnant people and their sexual partners? Participants will: * Give feedback about why they did or did not want to take the rapid test, and what their experience was taking the test; and * Share information about their health, pregnancy, and syphilis treatment (if applicable).
Recruiting
Has No Placebo
Maternity Centre of HamiltonLaura K Erdman, MD PhD FRCPC
Image of Benioff Children's Hospital - Oakland in Oakland, United States.

Decision Support for Lower Respiratory Infections in Children

6 - 17
All Sexes
Oakland, CA
Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.
Recruiting
Has No Placebo
Benioff Children's Hospital - Oakland (+2 Sites)Derek J Williams, MD, MPH
Have you considered Eryped clinical trials? We made a collection of clinical trials featuring Eryped, we think they might fit your search criteria.Go to Trials
Image of University of Pennsylvania Primary Care Practice in Philadelphia, United States.

Rapid Testing for Upper Respiratory Tract Infection

18+
All Sexes
Philadelphia, PA
The goal of this study is to understand the use of point of care (POC) testing devices in primary care offices to help clinicians diagnose and appropriately treat patients who have symptoms of upper respiratory infections (URIs). The study will use the BIOFIRE® SPOTFIRE® Respiratory (R) Panel testing device, which is FDA-cleared and CLIA-Waived. This panel can identify up to 15 different viruses and bacteria that can cause URIs. These POC devices will be installed in primary care clinics within the University of Pennsylvania Health System. Patients who come to the clinic with cold-like symptoms (runny nose, cough) will be offered the test. If the patient agrees to the test, their clinician will use a swab to take a small sample of fluid from their nose. This swab will then be tested within the POC device and results will be available within 15 minutes. The results of this sample will be shared with the patient, and their clinician can use the results to help decide the most appropriate medical treatment for the patient. Patients who agree to take the test will be asked to answer a short survey about the test and their experience. Clinicians will also be surveyed to share their thoughts with using the test in their clinics. Focus groups of practice staff and clinicians will also be conducted to understand any potential challenges for using this test in practice. Results from the tests and the surveys will help researchers understand the value of the test to support antibiotic stewardship efforts in primary care clinic settings.
Waitlist Available
Has No Placebo
University of Pennsylvania Primary Care Practice
Have you considered Eryped clinical trials? We made a collection of clinical trials featuring Eryped, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security